ACH-CANDESARTAN 32 MG
CANDESARTAN CILEXETIL : 32 MG · DIN 02379295 · ACCORD HEALTHCARE INC
Health Canada status: MARKETED
What is ACH-CANDESARTAN?
ACH-CANDESARTAN 32 MG contains CANDESARTAN CILEXETIL : 32 MG. It is listed in the Health Canada Drug Product Database under DIN 02379295, held by ACCORD HEALTHCARE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Aug-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACH-CANDESARTAN used for?
Treatment of mild to moderate essential hypertension in adults and children (6-17 years); treatment of NYHA Class II-III heart failure with ejection fraction ≤ 40%.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02379295 |
|---|---|
| Brand name | ACH-CANDESARTAN |
| Generic / active ingredient | CANDESARTAN CILEXETIL : 32 MG |
| Manufacturer | ACCORD HEALTHCARE INC |
| Strength | 32 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09CA06 CANDESARTAN |
| AHFS class | 24:32.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Aug-2014 |
| Original market date | 2012-02-16 00:00:00 |
How is it administered?
Hypertension: 8-32 mg once daily (initial 16 mg). Heart Failure: initial 4 mg once daily, target 32 mg by doubling at 2-week intervals. Take with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentioned but content not shown), typically store at 15-30°C.
How is it supplied?
Blister packs of 30 tablets and bottles of 100 tablets.
Contraindications
Hypersensitivity; pregnancy; nursing; children <1 year; combination with aliskiren in patients with diabetes or renal impairment; hereditary galactose intolerance.
Warnings and precautions
Fetal toxicity risk; dual blockade of RAS; hypotension (especially volume-depleted patients); hyperkalemia; renal function changes in susceptible individuals.
What can be used instead?
Other Canadian products sharing ATC code C09CA06 CANDESARTAN. 51 of 126 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-CANDESARTAN | 16 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02379287 |
| ACH-CANDESARTAN | 8 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02379279 |
| AG-CANDESARTAN TABLETS | 16 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500809 |
| AG-CANDESARTAN TABLETS | 32 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500817 |
| AG-CANDESARTAN TABLETS | 8 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500795 |
| APO-CANDESARTAN TABLETS | 16 MG | TABLET | APOTEX INC | MARKETED | DIN 02541300 |
| APO-CANDESARTAN TABLETS | 32 MG | TABLET | APOTEX INC | MARKETED | DIN 02541319 |
| APO-CANDESARTAN TABLETS | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02541289 |
| APO-CANDESARTAN TABLETS | 8 MG | TABLET | APOTEX INC | MARKETED | DIN 02541297 |
| ATACAND | 16 MG | TABLET | CHEPLAPHARM ARZNEIMITTEL GMBH | MARKETED | DIN 02239092 |
Who else supplies CANDESARTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CANDESARTAN appears in 1023 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.